Gynomax Drug Interactions

Due to tinidazole absorption, the following interactions can be seen if used concomitantly with the drugs as follows: Acenocoumarol, Anisindione, Dicoumarol, Phenindione, Phenprocoumon, Warfarin: Increase in bleeding risk.
Cholestyramine: Decrease in the efficacy of tinidazole.
Cimetidine: Increase in plasma concentrations of tinidazole.
Cyclosporine: Increase in levels of cyclosporine.
Disulfiram: Central nervous system related effects (e.g. psychotic reactions).
Fluorouracil: Increase in plasma levels of fluorouracil and signs of a potential fluorouracil intoxication (granulocytopenia, anemia, thrombocytopenia, stomatitis, vomiting).
Fosphenytoin: Increase in fosphenytoin toxicity and/or decrease in plasma concentrations of tinidazole.
Ketoconazole: Increase in plasma concentrations of tinidazole.
Lithium: Increase in plasma concentrations of lithium and signs of lithium intoxication (weakness, shaking, polydipsia, confusion).
Phenobarbital: Decrease in plasma concentrations of tinidazole.
Phenytoin: Increase of a potential phenytoin intoxication and/or decrease in plasma concentrations of tinidazole.
Rifampin: Decrease in plasma concentrations of tinidazole.
Tacrolimus: Increase in levels of tacrolimus.
CYP3A4 inducers/inhibitors: Decrease in the efficacy of tinidazole or increase in the risk of adverse reactions (CYP3A4 inhibitors such as cimetidine and ketoconazole, may prolong the half-life and decrease the plasma clearance of tinidazole and increasing the plasma concentrations of tinidazole).
Due to tioconazole absorption, the following interactions can be seen if used concomitantly with the drugs as follows: Oxycodone: Simultaneous administration of tioconazole and oxycodone may increase the plasma concentration of oxycodone and decrease the clearance of oxycodone.
Due to lidocaine absorption, the following interactions can be seen if used concomitantly with the drugs as follows: Propranolol: Decrease in the plasma clearance of lidocaine.
Cimetidine: Decrease in the plasma clearance of lidocaine.
Antiarrhythmic products: Increase in lidocaine toxicity.
Phenytoin or barbiturates: Decrease in the plasma level of lidocaine.
Additional Information on Special Populations: No interaction study has been conducted in special population.
Additional Information on Pediatric Population: No interaction study has been conducted in pediatric population.